FINWIRES · TerminalLIVE
FINWIRES

Raymond James Initiates Milestone Pharmaceuticals at Strong Buy

By

Milestone Pharmaceuticals (MIST) has an average rating of buy and mean price target of $6.50, according to analysts polled by FactSet.